Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H16NO |
Molecular Weight | 166.2405 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC[N+](C)(C)c1cccc(c1)O
InChI
InChIKey=VWLHWLSRQJQWRG-UHFFFAOYSA-O
InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
Molecular Formula | C10H15NO |
Molecular Weight | 165.2326 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.rxlist.com/enlon-drug.htm
Sources: http://www.rxlist.com/enlon-drug.htm
Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
Originator
Sources: https://www.google.com/patents/US2647924
Curator's Comment:: reference retrieved from http://www.drugfuture.com/chemdata/edrophonium-chloride.html # Hoffmann La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
|||
Target ID: CHEMBL1914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21397501 |
|||
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8109771 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date4.92047991E11 |
|||
Preventing | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date4.92047991E11 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
0.5 mg/kg single, intravenous dose: 0.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
56.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
84.2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Tensilon and the diagnosis of myasthenia gravis: are we using the Tensilon test too much? | 2001 Sep |
|
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. | 2003 |
|
[Premonitory depression]. | 2003 |
|
Reversible and irreversible inhibitory activity of succinic and maleic acid derivatives on acetylcholinesterase. | 2003 Apr |
|
[Comparison between idiopathic achalasia and achalasia caused by Chagas' disease: a review on the publications about the subject]. | 2003 Apr-Jun |
|
[Blepharospasm in a patient with thymoma and positive anti-acetylcholine receptor antibody]. | 2003 Aug |
|
Ocular myasthenia gravis associated with euthyroid ophthalmopathy. | 2003 Dec |
|
Natural monomeric form of fetal bovine serum acetylcholinesterase lacks the C-terminal tetramerization domain. | 2003 Dec 30 |
|
Development of generalized disease at 2 years in patients with ocular myasthenia gravis. | 2003 Feb |
|
Esophageal manometry in patients with clinical symptoms mimicking esophageal origin: a hospital-based ten-year experience. | 2003 Jan |
|
Simplified tilt table test protocol with continuous upright position during medication administration and no hydration. | 2003 Jan |
|
Positive tensilon test and intracranial tumor: a case report. | 2003 Jul |
|
Clinical profile of myasthenia gravis in the Sultanate of Oman. | 2003 Jul |
|
Chiropractic care of a pediatric patient with myasthenia gravis. | 2003 Jul-Aug |
|
The edrophonium test. | 2003 Mar |
|
Endplate dysfunction causing respiratory failure in a patient with prior paralytic poliomyelitis. | 2003 Mar |
|
Utility of ambulatory 24-hour esophageal pH and motility monitoring in noncardiac chest pain: report of 90 patients and review of the literature. | 2003 May |
|
Assessment of esophageal function in patients with myasthenia gravis. | 2003 May |
|
Facile synthesis of [11C]edrophonium and its analogues as new potential PET imaging agents for heart acetylcholinesterase. | 2003 May 19 |
|
[Response to thymectomy in patients with thymoma]. | 2003 Nov-Dec |
|
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. | 2003 Oct |
|
Cage amines as the stopper inhibitors of cholinesterases. | 2003 Sep 1 |
|
Prevalence of esophageal disorders in patients with recurrent chest pain. | 2004 |
|
Myasthenia gravis in childhood. | 2004 |
|
Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome. | 2004 Apr 13 |
|
Anticholinesterase therapy for patients with ophthalmoplegia following snake bites: report of two cases. | 2004 Aug |
|
Respiratory failure as a first presentation of myasthenia gravis. | 2004 Dec |
|
Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports. | 2004 Feb |
|
Clinical and neurophysiological characteristics of congenital myasthenic syndromes presenting in early infancy. | 2004 Jan |
|
Does acetylcholinesterase inhibition affect catecholamine secretion by adrenomedullary cells? | 2004 Jul |
|
Persistent diplopia after retrobulbar anesthesia. | 2004 Jun |
|
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. | 2004 Mar |
|
Nitric oxide and cardiac muscarinic control in humans. | 2004 May |
|
Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. | 2004 Nov 16 |
|
A case of Lambert-Eaton myasthenic syndrome associated with atypical bronchopulmonary carcinoid tumor. | 2004 Oct |
|
Evaluation of mechanisms of azinphos-methyl resistance in the codling moth Cydia pomonella (L.). | 2004 Oct |
|
Painful sweating. | 2004 Oct 26 |
|
Pupil-sparing, painless compression of the oculomotor nerve by expanding basilar artery aneurysm: a case of ocular pseudomyasthenia. | 2004 Sep |
|
Ocular myasthenia gravis. | 2004 Sep |
|
'Dropped head sign' in myasthenia gravis. | 2004 Sep |
|
Sensory testing of the esophagus. | 2004 Sep |
|
Immunological and electrophysiological investigations of severe ptosis after bone marrow transplantation. | 2004 Sep |
|
Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. | 2004 Sep 11 |
|
Does this patient have myasthenia gravis? | 2005 Apr 20 |
|
Advances in the diagnosis of neuromuscular junction disorders. | 2005 Aug |
|
Edrophonium-induced right ventricular outflow tract tachycardia. | 2005 Jan |
|
Postinfectious myasthenia gravis: report of two children. | 2005 May |
|
Clinical utility of videofluorography with concomitant Tensilon administration in the diagnosis of bulbar myasthenia gravis. | 2005 May |
|
MG and LEMS overlap syndrome: case report with electrophysiological and immunological evidence. | 2005 May |
|
Management of myasthenia gravis. | 2005 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.rxlist.com/enlon-drug.htm
Enlon (edrophonium injection) ® Test in the Differential Diagnosis of Myasthenia Gravis:1-8
Intravenous Dosage (Adults): A tuberculin syringe containing 1 mL (10 mg) of Enlon (edrophonium injection) ® is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal muscle fasciculations and increased muscle weakness) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated.
Intramuscular Dosage (Adults): In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of Enlon (edrophonium injection) ®. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2mg) of Enlon (edrophonium injection) ® intramuscularly to rule out false-negative reactions.
For Use as a Curare Antagonist: Enlon (edrophonium injection) ® should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, Enlon (edrophonium injection) ® should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 01:15:50 UTC 2021
by
admin
on
Sat Jun 26 01:15:50 UTC 2021
|
Record UNII |
70FP3JLY7N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
||
|
NDF-RT |
N0000175723
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
||
|
NDF-RT |
N0000000177
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1546421
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
ALTERNATIVE | |||
|
312-48-1
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
3202
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
3752
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
Edrophonium
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
Edrophonium
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
D004491
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
70FP3JLY7N
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
SUB01860MIG
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
312-48-1
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
DB01010
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
988
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY | |||
|
C76137
Created by
admin on Sat Jun 26 01:15:50 UTC 2021 , Edited by admin on Sat Jun 26 01:15:50 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |